Document Detail


Entecavir for chronic hepatitis B: a review.
MedLine Citation:
PMID:  18223455     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Three nucleotide/nucleoside analogs are currently used for the treatment of chronic hepatitis B: lamivudine, adefovir dipivoxil, and entecavir. Lamivudine and adefovir are beneficial for oral administration and safety, but only a few of the patients treated experience a sustained response after therapy withdrawal. Entecavir, a cyclopentyl guanosine analog, is a potent inhibitor of chronic hepatitis B virus DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. In phase II and phase III clinical trials, entecavir was found to be superior to lamivudine for all primary end points evaluated in both nucleoside-naive and lamivudine-resistant patients as well as being effective in both HBeAg-positive and HBeAg-negative nucleoside-naive patients. Only one trial has shown evidence of cases of viral resistance to this drug. The approved dosage in treatment-naive patients is 0.5 mg per day orally, whereas in patients who have failed lamivudine therapy or are known to harbor lamivudine-resistant mutants, the approved dosage is 1.0 mg per day.
Authors:
Emilio Palumbo
Related Documents :
16688835 - Lamivudine therapy for children with chronic hepatitis b.
17133475 - Entecavir resistance is rare in nucleoside naïve patients with hepatitis b.
14688455 - Hepatitis b genotypes in chronic hepatitis b and lamivudine therapy.
12081605 - Thymosin-alpha1 and famciclovir combination therapy activates t-cell response in patien...
24159925 - Renal and urologic disorders in antiretroviral-treated patients with hiv infection or a...
12411025 - analysis about clinical data of intrauterine infection of hepatitis b virus
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Therapeutic drug monitoring     Volume:  30     ISSN:  0163-4356     ISO Abbreviation:  Ther Drug Monit     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-01-28     Completed Date:  2008-05-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7909660     Medline TA:  Ther Drug Monit     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  IM    
Affiliation:
Clinic of Paediatrics, Hospital of Sondrio, Foggia, Italy. emipalu2003@yahoo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / adverse effects,  pharmacology,  therapeutic use*
Guanine / adverse effects,  analogs & derivatives*,  pharmacology,  therapeutic use
Hepatitis B, Chronic / drug therapy*
Humans
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/entecavir; 73-40-5/Guanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessing joint attention and symbolic play in children with cochlear implants and multiple disabili...
Next Document:  Triptans in pregnancy.